Chugai Pharma USA clinical trials
Acquired by Hoffmann-La Roche, Oct 1, 2002 · source ↗
The registry lists 3 studies whose lead sponsor is Chugai Pharma USA. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 24, 2005.
- 3studies on the registry
- 0open to participants now
Before and after it joined Hoffmann-La Roche
- First submitted before Chugai Pharma USA became part of Hoffmann-La Roche
- 0
- First submitted after Chugai Pharma USA became part of Hoffmann-La Roche
- 3
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
All 3 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed3100%
Registry sponsor names on this page
- Chugai Pharma USA3 studies
Something wrong with this grouping? Tell us on the Hoffmann-La Roche page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Hoffmann-La Roche studies →
- Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic GastroparesisCompletedNCT00050882Phase 2
Sponsor listed in the registry: Chugai Pharma USA · First submitted after Chugai Pharma USA became part of Hoffmann-La Roche
- A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.CompletedNCT00055510Phase 2/3
Sponsor listed in the registry: Chugai Pharma USA · First submitted after Chugai Pharma USA became part of Hoffmann-La Roche
- An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast CancerCompletedNCT00051779Phase 1
Sponsor listed in the registry: Chugai Pharma USA · First submitted after Chugai Pharma USA became part of Hoffmann-La Roche